Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 in moderate-to-severe asthma
NCT06837922Phase 3Recruiting
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing MG-K10 with Placebo (2 arms). Primary endpoint: Primary purpose at 52 weeks. Started Mar 2025; status: recruiting.
02
Drugs
comekibart
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06837922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837922.